GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioHarvest Sciences Inc (XCNQ:BHSC) » Definitions » Debt-to-EBITDA

BioHarvest Sciences (XCNQ:BHSC) Debt-to-EBITDA : -1.01 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is BioHarvest Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioHarvest Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$28.06 Mil. BioHarvest Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$1.91 Mil. BioHarvest Sciences's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-29.60 Mil. BioHarvest Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioHarvest Sciences's Debt-to-EBITDA or its related term are showing as below:

XCNQ:BHSC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.97   Med: -0.42   Max: -0.09
Current: -2.97

During the past 10 years, the highest Debt-to-EBITDA Ratio of BioHarvest Sciences was -0.09. The lowest was -2.97. And the median was -0.42.

XCNQ:BHSC's Debt-to-EBITDA is ranked worse than
100% of 1431 companies
in the Consumer Packaged Goods industry
Industry Median: 2.12 vs XCNQ:BHSC: -2.97

BioHarvest Sciences Debt-to-EBITDA Historical Data

The historical data trend for BioHarvest Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioHarvest Sciences Debt-to-EBITDA Chart

BioHarvest Sciences Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.42 -0.31 -1.16 -2.29

BioHarvest Sciences Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.71 -1.07 -4.65 -1.82 -1.01

Competitive Comparison of BioHarvest Sciences's Debt-to-EBITDA

For the Packaged Foods subindustry, BioHarvest Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioHarvest Sciences's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioHarvest Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioHarvest Sciences's Debt-to-EBITDA falls into.



BioHarvest Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioHarvest Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(28.061 + 1.912) / -13.098
=-2.29

BioHarvest Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(28.061 + 1.912) / -29.596
=-1.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioHarvest Sciences  (XCNQ:BHSC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioHarvest Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioHarvest Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioHarvest Sciences (XCNQ:BHSC) Business Description

Traded in Other Exchanges
Address
1140-625 Howe Street, Vancouver, BC, CAN, V6C 2T6
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

BioHarvest Sciences (XCNQ:BHSC) Headlines

No Headlines